

Extensions of the Kermack-McKendrick model MATH 8xyz – Lecture 05


Julien Arino Department of Mathematics @ University of Manitoba Maud Menten Institute @ PIMS

julien.arino@umanitoba.ca

Winter 20XX

The University of Manitoba campuses are located on original lands of Anishinaabeg, Ininew, Anisininew, Dakota and Dene peoples, and on the National Homeland of the Red River Métis. We respect the Treaties that were made on these territories, we acknowledge the harms and mistakes of the past, and we dedicate ourselves to move forward in partnership with Indigenous communities in a spirit of Reconciliation and collaboration.

Outline



The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model
A model with vaccination
Antiviral resistance



Simple models for containment of a pandemic

Julien Arino^{1,*}, Fred Brauer², P. van den Driessche³, James Watmough⁴ and Jianhong Wu⁵

¹Department of Mathematics, University of Manitoba, Winnipeg,
Manitoba R3T 2N2, Canada

²Department of Mathematics, University of British Columbia,
Vancouver, British Columbia V6T 1Z2, Canada

³Department of Mathematics and Statistics, University of Victoria,
Victoria, British Columbia V8W 3P4, Canada

⁴Department of Mathematics and Statistics, University of New Brunswick,
Fredericton, New Brunswick E3B 5A3, Canada


⁵Department of Mathematics and Statistics, York University,
Toronto. Ontario M3J 1P3. Canada

SIR is a little too simple for many diseases:

No incubation period

➤ A lot of infectious diseases (in particular respiratory) have mild and less mild forms depending on the patient

⇒ model with SIR but also L(atent) and (A)symptomatic individuals, in which I are now symptomatic individuals



Basic reproduction number & Final size

We find the basic reproduction number

$$\mathcal{R}_0 = \beta \left(\frac{p}{\alpha} + \frac{\delta(1-p)}{\eta} \right) S_0 = \frac{\beta \rho}{\alpha} S_0$$
 (1)

where


$$\rho = \alpha \left(\frac{p}{\alpha} + \frac{\delta(1-p)}{\eta} \right)$$

The final size relation takes the form

$$S_0(\ln S_0 - \ln S_\infty) = \mathcal{R}_0(S_0 - S_\infty) + \frac{\mathcal{R}_0 I_0}{a}$$
 (2)

p. 4

Adding treatment






Figure 3. Total number of doses used in a population of 1000 individuals over the course of the outbreak as a function of the mean times to treatment and prophylaxis (in days), for \mathcal{R}_0 = 1.5, with S_0 =999 and I_0 =1.




Figure 4. Total cases as a function of the treatment rates, for $\mathcal{R}_0 = 1.5$, with $S_0 = 999$ and $I_0 = 1$.

5. CONCLUSIONS

Compartmental models facilitate the analysis of sensitivity of the model to errors in measuring parameters or to changes in the control parameters. This is particularly valuable before the beginning of an epidemic when the values of some parameters are only guesses. For example, a sensitivity analysis of our model shows the importance of estimating the parameter p representing the fraction of latent members that will develop symptoms. This parameter is almost impossible to determine accurately, and it is taken to be 2/3 in Longini et al. (2004) and 1/2 in Ferguson et al. (2005). In view of the many uncertainties in estimating parameters for pandemic influenza, it is important to consider a large range of values, and the simplicity of calculation offered by a deterministic compartmental model lends itself to doing this as an initial step before more complicated models such as those of Ferguson et al. (2005) and Longini et al. (2005) are invoked. The calculations reported here involve nothing more complicated than the solution of a system of two transcendental equations.

The SLIAR model Computing the final size more efficiently

A variation on the SLIAR model A model with vaccination Antiviral resistance

pp. **159–175**

A FINAL SIZE RELATION FOR EPIDEMIC MODELS

Julien Arino

Department of Mathematics, University of Manitoba Winnipeg, Manitoba R3T 2N2, Canada

FRED BRAHER

Department of Mathematics, University of British Columbia Vancouver, BC V6T 1Z2, Canada

P. VAN DEN DRIESSCHE

Department of Mathematics and Statistics, University of Victoria Victoria, B.C. V8W 3P4, Canada

James Watmough

Department of Mathematics and Statistics, University of New Brunswick Fredericton, N.B. E3B 5A3, Canada

JIANHONG WII

Department of Mathematics and Statistics, York University Toronto, Ontario M3J 1P3, Canada

(Communicated by Zhilan Feng)

A method for computing \mathcal{R}_0 in epidemic models

► This method is not universal! It works in a relatively large class of models, but not everywhere

► If it doesn't work, the next generation matrix method does work, **but** should be considered only for obtaining the reproduction number, not to deduce LAS

► Here, I change the notation in the paper, for convenience

Standard form of the system

Suppose system can be written in the form

$$S' = b(S, I, R) - DS\beta(S, I, R)hI$$
 (3a)

$$I' = \Pi DS\beta(S, I, R)hI - VI$$
 (3b)

$$\mathbf{R}' = \mathbf{f}(\mathbf{S}, \mathbf{I}, \mathbf{R}) + \mathbf{W}\mathbf{I} \tag{3c}$$

where $\mathbf{S} \in \mathbb{R}^m$, $\mathbf{I} \in \mathbb{R}^n$ and $\mathbf{R} \in \mathbb{R}^k$ are susceptible, infected and removed compartments, respectively

IC are ≥ 0 with at least one of the components of I(0) positive

$$S' = b(S, I, R) - DS\beta(S, I, R)hI$$
 (3a)

- **b** : $\mathbb{R}^m_+ \times \mathbb{R}^n_+ \times \mathbb{R}^k_+ \to \mathbb{R}^m$ continuous function encoding recruitment and death of uninfected individuals
- ▶ $\mathbf{D} \in \mathbb{R}^{m \times m}$ diagonal with diagonal entries $\sigma_i > 0$ the relative susceptibilities of susceptible compartments, with convention that $\sigma_1 = 1$
- Scalar valued function $\beta : \mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}_+$ represents infectivity, with, e.g., $\beta(S, I, R) = \beta$ for mass action
- $h \in \mathbb{R}^n$ row vector of relative horizontal transmissions

$$I' = \Pi DS\beta(S, I, R)hI - VI$$
 (3b)

- ▶ $\Pi \in \mathbb{R}^{n \times m}$ has (i, j) entry the fraction of individuals in j^{th} susceptible compartment that enter i^{th} infected compartment upon infection
- ▶ $\mathbf{D} \in \mathbb{R}^{m \times m}$ diagonal with diagonal entries $\sigma_i > 0$ the relative susceptibilities of susceptible compartments, with convention that $\sigma_1 = 1$
- Scalar valued function $\beta : \mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}_+$ represents infectivity, with, e.g., $\beta(\mathbf{S}, \mathbf{I}, \mathbf{R}) = \beta$ for mass action
- $h \in \mathbb{R}^n$ row vector of relative horizontal transmissions
- $\mathbf{V} \in \mathbb{R}^{n \times n}$ describes transitions between infected states and removals from these states due to recovery or death

$$\mathbf{R}' = \mathbf{f}(\mathbf{S}, \mathbf{I}, \mathbf{R}) + \mathbf{W}\mathbf{I} \tag{3c}$$

- ▶ **f** : $\mathbb{R}_+^m \times \mathbb{R}_+^n \times \mathbb{R}_+^k \to \mathbb{R}^k$ continuous function encoding flows into and out of removed compartments because of immunisation or similar processes
- ▶ **W** ∈ $\mathbb{R}^{k \times n}$ has (i, j) entry the rate at which individuals in the j^{th} infected compartment move into the i^{th} removed compartment

p. 14

Suppose $\textbf{\textit{E}}_0$ is a locally stable disease-free equilibrium (DFE) of the system without disease, i.e., an EP of

$$\mathbf{S}' = \mathbf{b}(\mathbf{S}, \mathbf{0}, \mathbf{R})$$

 $\mathbf{R}' = \mathbf{f}(\mathbf{S}, \mathbf{0}, \mathbf{R})$

Theorem 1

Let

$$\mathcal{R}_0 = \beta(\mathbf{S}_0, \mathbf{0}, \mathbf{R}_0) h \mathbf{V}^{-1} \mathbf{\Pi} \mathbf{D} \mathbf{S}_0 \tag{4}$$

- ▶ If \mathcal{R}_0 < 1, the DFE \boldsymbol{E}_0 is a locally asymptotically stable EP of (3)
- ▶ If $\mathcal{R}_0 > 1$, the DFE **E**₀ of (3) is unstable

If no demography (epidemic model), then just \mathcal{R}_0 , of course

Final size relations

Assume no demography, then system should be writeable as

$$\mathbf{S}' = -\mathbf{D}\mathbf{S}\beta(\mathbf{S}, \mathbf{I}, \mathbf{R})\mathbf{h}\mathbf{I}$$
 (5a)
 $\mathbf{I}' = \mathbf{\Pi}\mathbf{D}\mathbf{S}\beta(\mathbf{S}, \mathbf{I}, \mathbf{R})\mathbf{h}\mathbf{I} - \mathbf{V}\mathbf{I}$ (5b)

$$\mathbf{R}' = \mathbf{WI}$$
 (5c)

For $w(t) \in \mathbb{R}^n_+$ continuous, define

$$w_{\infty} = \lim_{t \to \infty} w(t)$$
 and $\hat{w} = \int_{0}^{\infty} w(t) dt$

Define the row vector

$$\mathbb{R}^m \ni \Gamma = (\Gamma_1, \dots, \Gamma_m) = \beta(S_0, 0, R_0) h V^{-1} \Pi D$$

then

$$\mathcal{R}_0 = \Gamma \mathcal{S}(0)$$

p. 17 –

Suppose incidence is mass action, i.e., $\beta(S, I, R) = \beta$ and m > 1

Then for i = 1, ..., m, express $S_i(\infty)$ as a function of $S_1(\infty)$ using

$$oldsymbol{\mathcal{S}}_i(\infty) = oldsymbol{\mathcal{S}}_i(0) \left(rac{oldsymbol{\mathcal{S}}_1(\infty)}{oldsymbol{\mathcal{S}}_1(0)}
ight)^{\sigma_i/\sigma_1}$$

then substitute into

$$egin{aligned} rac{1}{\sigma_i} \ln \left(rac{oldsymbol{\mathcal{S}}_i(0)}{oldsymbol{\mathcal{S}}_i(\infty)}
ight) &= \Gamma oldsymbol{\mathcal{D}}^{-1} \left(oldsymbol{\mathcal{S}}(0) - oldsymbol{\mathcal{S}}(\infty)
ight) + eta oldsymbol{hV}^{-1} oldsymbol{I}(0) \ &= rac{1}{\sigma_1} \ln \left(rac{oldsymbol{\mathcal{S}}_1(0)}{oldsymbol{\mathcal{S}}_1(\infty)}
ight) \end{aligned}$$

which is a final size relation for the general system when $S_i(0) > 0$

If incidence is mass action and m=1 (only one susceptible compartment), reduces to the KMK form

$$\ln\left(\frac{S_0}{S_\infty}\right) = \frac{\mathcal{R}_0}{S_0}(S_0 - S_\infty) + \beta h \mathbf{V}^{-1} \mathbf{I}_0$$
 (6)

5. 19

In the case of more general incidence functions, the final size relations are inequalities of the form, for i = 1, ..., m,

$$\operatorname{In}\left(rac{oldsymbol{S}_{i}(0)}{oldsymbol{S}_{i}(\infty)}
ight) \geq \sigma_{i}\Gammaoldsymbol{D}^{-1}\left(oldsymbol{S}(0)-oldsymbol{S}(\infty)
ight) + \sigma_{i}eta(K)oldsymbol{h}oldsymbol{V}^{-1}oldsymbol{I}(0)$$


where K is the initial total population

The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model
A model with vaccination
Antiviral resistance

The SLIAR model

► Paper we have already seen: Arino, Brauer, PvdD, Watmough & Wu. Simple models for containment of a pandemic, *Journal of the Royal Society Interface* (2006)

► However, suppose additionally that *L* are also infectious



Here, S = S, $I = (L, I, A)^T$ and R = R, so m = 1, n = 3 and

$$m{h} = [\varepsilon \ 1 \ \delta], \quad m{D} = 1, \quad m{\Pi} = \begin{pmatrix} 1 \\ 0 \\ 0 \end{pmatrix} \quad \text{and} \quad m{V} = \begin{pmatrix} \kappa & 0 & 0 \\ -p\kappa & \alpha & 0 \\ -(1-p)\kappa & 0 & \eta \end{pmatrix}$$

Incidence is mass action so $\beta(\mathbf{E}_0) = \beta$ and thus

$$egin{aligned} \mathcal{R}_0 &= eta \, \mathbf{hV}^{-1} \mathbf{\Pi} \, \mathbf{D} \mathbf{S}_0 \ &= eta \, \left[arepsilon \, \mathbf{1} \, \delta
ight] \left(egin{array}{ccc} 1/\kappa & 0 & 0 \ p/lpha & 1/lpha & 0 \ (1-p)/\eta & 0 & 1/\eta \end{array}
ight) \left(egin{array}{ccc} 1 \ 0 \ 0 \end{array}
ight) S_0 \ &= eta S_0 \left(rac{arepsilon}{\kappa} + rac{p}{lpha} + rac{\delta(1-p)}{n}
ight) \end{aligned}$$

For final size, since m = 1, we can use (6):

$$\ln\left(rac{S_0}{S_\infty}
ight) = rac{\mathcal{R}_0}{S_0}(S_0-S_\infty) + eta oldsymbol{h} oldsymbol{V}^{-1} oldsymbol{I}_0$$

Suppose $I_0 = (0, I_0, 0)$, then

$$\ln\left(\frac{S_0}{S_\infty}\right) = \mathcal{R}_0 \frac{S_0 - S_\infty}{S_0} + \frac{\beta}{\alpha} I_0$$


If $I_0 = (L_0, I_0, A_0)$, then

$$\ln\left(\frac{S_0}{S_\infty}\right) = \mathcal{R}_0 \frac{S_0 - S_\infty}{S_0} + \beta \left(\frac{\varepsilon}{\kappa} + \frac{\rho}{\alpha} + \frac{\delta(1-\rho)}{\eta}\right) L_0 + \frac{\beta\delta}{\eta} A_0 + \frac{\beta}{\alpha} I_0$$

The SLIAR model Computing the final size more efficiently A variation on the SLIAR model

A model with vaccination
Antiviral resistance

A model with vaccination



A model with vaccination

Fraction γ of S_0 are vaccinated before the epidemic; vaccination reduces probability and duration of infection, infectiousness and reduces mortality

$$S_{U}' = -\beta S_{U}[I_{U} + \sigma_{I}I_{V}]$$
 (7a)

$$S_{V}' = -\sigma_{S}\beta S_{V}[I_{U} + \sigma_{I}I_{V}]$$
 (7b)

$$L_{U}' = \beta S_{U}[I_{U} + \sigma_{I}I_{V}] - \kappa_{U}L_{U}$$
 (7c)

$$L_{V}' = \sigma_{S}\beta S_{V}[I_{U} + \sigma_{I}I_{V}] - \kappa_{V}L_{V}$$
 (7d)

$$I_{U}' = \kappa_{U}L_{U} - \alpha_{U}I_{U}$$
 (7e)

$$I_{V}' = \kappa_{V}L_{V} - \alpha_{V}I_{V}$$
 (7f)

$$R' = f_{U}\alpha_{U}I_{I} + f_{V}\alpha_{V}I_{V}$$
 (7g)

with
$$S_U(0) = (1 - \gamma)S_0$$
 and $S_V(0) = \gamma S_0$

Here, m = 2, n = 4,

$$m{h} = [0 \ 0 \ 1 \ \sigma_I], \quad m{D} = \begin{pmatrix} 1 & 0 \\ 0 & \sigma_S \end{pmatrix}, \quad m{\Pi} = \begin{pmatrix} 1 & 0 \\ 0 & 1 \\ 0 & 0 \\ 0 & 0 \end{pmatrix}$$

and

$$\mathbf{V} = egin{pmatrix} \kappa_{U} & 0 & 0 & 0 \ 0 & \kappa_{V} & 0 & 0 \ -\kappa_{U} & 0 & lpha_{U} & 0 \ 0 & -\kappa_{V} & 0 & lpha_{V} \end{pmatrix}$$

p. 27 –

So

$$\Gamma = \left[\frac{\beta}{\alpha_{\textit{U}}} \, \frac{\sigma_{\textit{I}} \sigma_{\textit{S}} \beta}{\alpha_{\textit{V}}}\right], \quad \mathcal{R}_{\textit{c}} = \textit{S}_{\textit{0}} \beta \left(\frac{1-\gamma}{\alpha_{\textit{U}}} + \frac{\sigma_{\textit{I}} \sigma_{\textit{S}} \gamma}{\alpha_{\textit{V}}}\right)$$

and the final size relation is

$$\ln\left(\frac{(1-\gamma)S_U(0)}{S_U(\infty)}\right) = \frac{\beta}{\alpha_U}[(1-\gamma)S_U(0) - S_U(\infty)] + \frac{\sigma_I\beta}{\alpha_V}[\gamma S_V(0) - S_V(\infty)] + \frac{\beta}{\alpha_U}I_0$$

$$S_V(\infty) = \gamma S_U(0) \left(\frac{S_U(\infty)}{(1-\gamma)S_0} \right)^{\sigma_S}$$

The SLIAR model
Computing the final size more efficiently
A variation on the SLIAR model
A model with vaccination
Antiviral resistance

BMC Infectious Diseases



Research article

Open Access

Antiviral resistance during pandemic influenza: implications for stockpiling and drug use

Julien Arino^{1,2}, Christopher S Bowman^{2,3} and Seyed M Moghadas*^{2,4,5}

Address: ¹Department of Mathematics, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada, ²Institute for Biodiagnostics, National Research Council Canada, Winnipeg, Manitoba R3B 1Y6, Canada, ³Department of Electrical and Computer Engineering, University of Manitoba, Winnipeg, Manitoba R3T 5V6, Canada, ⁴Department of Mathematics and Statistics, University of Winnipeg, Winnipeg, Manitoba R3B 2E9, Canada and ³Department of Statistics, University of Manitoba, Winnipeg, Manitoba R3T 2N2, Canada

Email: Julien Arino - arinoj@cc.umanitoba.ca; Christopher S Bowman - chris.bowman@nrc-cnrc.gc.ca; Seyed M Moghadas* - seyed.moghadas@nrc-cnrc.gc.ca

* Corresponding author

Published: 22 January 2009


BMC Infectious Diseases 2009. **9**:8 doi:10.1186/1471-2334-9-8

Received: 5 August 2008 Accepted: 22 January 2009

Adapting treatment to counter emergence of resistance

This work was undertaken at the request of the Public Health Agency of Canada during the pandemic preparadness phase prior to the 2009 p-H1N1 pandemic

Problem: we have antivirals to use against influenza, either prophylactically or curatively. Using these antivirals may promote the emergence of antiviral-resistant strains. How do we minimise this risk?



Bibliography I